Sanofi Consumer Healthcare
4,443.20
-92.80(-2.05%)
Market Cap₹10,232.97 Cr
PE Ratio43.28
IndustryHealthcare
Company Performance:
1D-2.05%
1M+3.87%
6M-13.51%
1Y-8.94%
5Y-9.39%
View Company Insightsright
More news about Sanofi Consumer Healthcare
13Nov 25
Sanofi Consumer Healthcare India Reports Strong Q3 Results with 46% Revenue Growth
Sanofi Consumer Healthcare India Limited announced strong Q3 results with revenue up 46% to ₹2,339.00 million and net profit increasing 40% to ₹629.00 million. Domestic sales grew 20% while export sales surged over 1000%. The company successfully relaunched all previously recalled products, including Depura Adult, Combiflam Suspension, Allegra Suspension, and Depura Kids. For the nine-month period, revenue grew 13% to ₹6,274.00 million with net profit up 27% to ₹1,736.00 million. The company's portfolio includes brands like Allegra, DePURA, Avil, and Combiflam in categories such as Allergy, Digestive Wellness, Pain Care, and Multivitamins.
 no imag found
16Oct 25
Sanofi Consumer Healthcare India Appoints Richard D'souza as CFO
Sanofi Consumer Healthcare India Limited has appointed Richard D'souza as its new Chief Financial Officer, effective October 16, 2025. D'souza brings over 25 years of leadership experience in finance, with expertise in financial strategy, M&A, investor relations, governance, and digital transformation. He previously served as Head of Finance at Bajaj Consumer Care and has experience in multinational and listed organizations in the FMCG and consumer goods sectors. The appointment aims to strengthen Sanofi's financial leadership and drive future growth.
 no imag found
10Oct 25
Sanofi Consumer Healthcare India CFO Narahari Naidu to Step Down
Narahari Naidu, CFO of Sanofi Consumer Healthcare India Limited, has resigned effective October 15, 2025, to pursue new career opportunities. The company has notified the BSE and NSE in compliance with SEBI regulations. Naidu expressed gratitude in his resignation email. No successor has been announced yet.
 no imag found
04Aug 25
Sanofi Consumer Healthcare India Appoints New CFO Amid Strong Q2 Performance
Sanofi Consumer Healthcare India has appointed Mr. Narahari Naidu as CFO effective August 4th, 2025. The company reported impressive Q2 2025 results with revenue at ₹2,209.00 million, up 28.21% YoY, and net profit at ₹607.00 million, a 109.31% increase from Q2 2024. The company successfully relaunched Depura Adult and Combiflam Suspension, contributing to strong performance. An exceptional gain of ₹66.00 million was recorded from reversing excess demerger-related provisions.
 no imag found
04Aug 25
Sanofi Consumer Healthcare India Reports Strong Q1 Results with 28% Revenue Growth
Sanofi Consumer Healthcare India Limited reported impressive Q1 financial results. Revenue from operations increased by 28% to ₹2,209.00 million, while net profit surged by 109% to ₹607.00 million compared to the previous year. Total income rose by 31% to ₹2,265.00 million. The company successfully relaunched Combiflam Suspension and is working on bringing back other recalled products. An exceptional gain of ₹66.00 million was recorded from reversing excess demerger-related provisions. The Board approved the appointment of Mr. Narahari Naidu as the new Chief Financial Officer.
 no imag found
02May 25
Sanofi Consumer Healthcare India Reports Mixed Q4 Results Amid Product Recalls
Sanofi Consumer Healthcare India Limited (SCHIL) released Q4 2025 results, showing revenue decline but improved profitability. Revenue dropped 22% YoY to ₹1,726.00 crore due to product recalls. Net profit fell 20.3% YoY to ₹500.00 crore but increased sequentially. EBITDA decreased to ₹640.00 crore, while EBITDA margin slightly improved to 37.08%. The company has completed most product recalls and relaunched Depura Adult. Management remains focused on bringing back other key products and improving market position.
 no imag found
25Apr 25
Sanofi Consumer Healthcare Faces Potential 26% Stake Acquisition by Opal Bidco Sas and Clayton, Dubilier & Rice Fund
Opal Bidco Sas, with Clayton, Dubilier & Rice Fund XII, L.P., has announced an open offer to acquire up to 26% stake (59,87,962 equity shares) in Sanofi Consumer Healthcare India Limited. The offer, made to public shareholders, complies with SEBI regulations. Key dates include the public announcement on October 21, 2024, and the final letter of offer issuance on April 12, 2025. This potential ownership shift could significantly impact the company's strategic direction and the Indian pharmaceutical market.
 no imag found
24Apr 25
Opal Bidco SAS Proposes 26% Stake Acquisition in Sanofi Consumer Healthcare India
Opal Bidco SAS, in association with Clayton, Dubilier & Rice Fund, has announced an open offer to acquire a 26% stake (59,87,962 equity shares) in Sanofi Consumer Healthcare India Limited. The offer timeline spans from October 21, 2024, to April 24, 2025, with key events including public announcements, detailed statements, and letter of offer issuance. This move could potentially impact the company's strategic direction and operations, and is being conducted in compliance with SEBI regulations.
 no imag found
20Feb 25
Sanofi Consumer Healthcare Declares ₹55 Dividend, Reports Strong FY2024 Performance
Sanofi Consumer Healthcare India Limited (SCHIL) has declared a final dividend of ₹55 per equity share for FY2024, subject to shareholder approval. The company reported total income of ₹7,375 million and net profit of ₹1,810 million for the year ended December 31, 2024. Revenue from operations grew by 30.4% to ₹7,245 million. SCHIL completed its demerger from Sanofi India Limited and listed on NSE and BSE in September 2024. The company voluntarily recalled Allegra and Combiflam Suspensions in July 2024 as a precautionary measure.
 no imag found
20Feb 25
Sanofi Consumer Healthcare: Q4 Profit Drops 35%, Declares ₹55 Dividend
Sanofi Consumer Healthcare India Limited (SCHIL) reported a significant downturn in its Q4 2024 financial results. Revenue decreased by 24% to ₹170.7 crore, while net profit fell by 34.8% to ₹44.3 crore compared to Q4 2023. EBITDA also declined by 30.6% to ₹61.1 crore, with margins contracting to 36.4%. Despite the challenging quarter, the company declared a final dividend of ₹55 per share for FY2024, subject to shareholder approval.
 no imag found
Sanofi Consumer Healthcare
4,443.20
-92.80
(-2.05%)
1 Year Returns:-8.94%
Industry Peers
Sun Pharmaceutical
1,825.90
(+0.72%)
Divis Laboratories
6,352.50
(-0.31%)
Torrent Pharmaceuticals
4,431.20
(+0.08%)
Dr Reddys Laboratories
1,325.50
(+0.83%)
Cipla
1,329.50
(-0.30%)
Lupin
2,344.60
(+0.31%)
Zydus Life Science
921.75
(-0.15%)
Mankind Pharma
2,243.80
(+0.27%)
Aurobindo Pharma
1,304.80
(+1.47%)
Alkem Laboratories
5,544.50
(-1.28%)